FinIP trial
The Finnish Invasive Pneumococcal disease (FinIP) vaccine trial has been conducted in collaboration with GlaxoSmithKline Vaccines, Finnish health care centres and the Tampere University Vaccine Research Centre starting early 2009.
The trial was designed to assess the effectiveness of the ten-valent pneumococcal conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease, pneumonia and otitis media. Over 47 000 children between 6 weeks and 18 months of age were enrolled from February 2009 through October 2010 into this nation-wide, cluster-randomised, double-blind trial. Outcome data have been collected using national health registers.
